Weekly Paclitaxel for Recurrent Ovarian Cancer: Does Weekly Administration at Primary Diagnosis Impact Efficacy and Toxicity at Recurrence?

Journal article

Peer reviewed

Camille C. Gunderson, Alexa Papaila, Kai Ding, Amelia M. Jernigan, Haider Mahdi, Sarah Bedell, David S. Miller, Bradley J. Monk and Kathleen N. Moore

Gynecologic oncology, Vol.143(1), pp.204-204

10/01/2016

Metrics

1 Record Views

Title: Weekly Paclitaxel for Recurrent Ovarian Cancer: Does Weekly Administration at Primary Diagnosis Impact Efficacy and Toxicity at Recurrence?
Creators: Camille C. Gunderson - Oklahoma State University Oklahoma City
Alexa Papaila - Oklahoma State University Oklahoma City
Kai Ding - Oklahoma State University Oklahoma City
Amelia M. Jernigan - Cleveland Clinic
Haider Mahdi - Cleveland Clinic
Sarah Bedell - The University of Texas Southwestern Medical Center
David S. Miller - The University of Texas Southwestern Medical Center
Bradley J. Monk - St. Joseph's Hospital and Medical Center
Kathleen N. Moore - University of Oklahoma
Publication Details: Gynecologic oncology, Vol.143(1), pp.204-204
Publisher: Elsevier Inc
Identifiers: 991005969164502656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article